Analyst Research Report Snapshot

Title:

BIONOMICS - 105 COMBINATION STRATEGY

Price:

$10.00

Provider:

Edison Investment Research

Date:

11 Aug 2011

Pages:

8

Type:

AcrobatPDF

Companies referenced:

BNO.AX 4508.T NOVN.VX ROG.VX TRGT.OQ

Available for Immediate Download
Summary:

Bionomics is to focus future development of its vascular disrupting agent BNC105 on combinations with chemotherapy, after a review of interim data from the two Phase II studies. Its RCC study will continue, while the single-agent study in mesothelioma will be closed in favour of a future combination strategy. A new Phase II study will start in early 2012 in ovarian cancer, with the drug given with standard doublet chemotherapy. The shift should not materially change the attractiveness or potential of the drug. Bionomics’ investment case remains centred on securing big pharma partnerships for this compound and BNC210 (anxiety, pre-Phase II).

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.